Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Carreño-Tarragona Gonzalo, Gil-Manso Rodrigo, Hernández-Boluda Juan Carlos, Martínez-Ávila José Carlos, Bellosillo Beatriz, Pérez-López Raúl, Segura Adrián, Ferrer-Marín Francisca, Arellano-Rodrigo Eduardo, Angona Anna, García-Gutiérrez Valentín, Noya María Soledad, Blanco Ángela, Zamora Lurdes, Navarro Miguel, Senín Alicia, Magro Elena, Pastor-Galán Irene, Mata-Vázquez María Isabel, Morales María Luz, Cuevas Beatriz, Vélez Patricia, Mora Elvira, Martínez-Bilbao Cristina, Colmenares Rafael, Alonso Juan Manuel, Pérez-Encinas Manuel, Caballero-Navarro Gonzalo, Cortés Miguel Ángel, Santaliestra Marta, Raya José María, Blanco-Sánchez Alberto, Hernández-Rivas Jesús María, Martínez-López Joaquín, Ayala Rosa, Álvarez-Larrán Alberto, MPN Spanish Group (GEMFIN)
Аннотация
Triple-negative essential thrombocythemia (TN-ET) represents a diagnostic and therapeutic challenge. The aim of the present study was to identify prognostic factors useful for tailoring treatment. 241 TN-ET patients with myeloid panel sequencing and confirmatory bone marrow biopsy were selected. Pathogenic/likely pathogenic variants were identified in 19.5% of patients. Mutation carriers were older (median age 66 years vs. 53, p < 0.001) and had a higher frequency of prior thrombosis (19.6% vs. 6.5%, p = 0.013). Presence of pathogenic/likely pathogenic variants was associated with leukemic progression (HR 12.608; 95% CI: 2.616-60.775, p = 0.002) and lower overall survival (HR 3.008; 95% CI: 1.43-6.327, p = 0.004). ASXL1 (p = 0.004), CBL (p < 0.001), EZH2 (p < 0.001), and ZRSR2 (p < 0.001) mutations were associated with inferior leukemia-free survival. Age over 60 years, previous thrombosis, and cardiovascular risk factors were associated with higher thrombotic risk. Revised IPSET-thrombosis was useful for risk stratification (10-year probability of overall thrombosis: 30%, 15%, and 6% for high-, intermediate-, and very-low risk patients, respectively, p < 0.001). ARTS score refined arterial thrombosis stratification (10 years probability: 25% and 6% for high- and low-risk, respectively, p < 0.001). Progression to myelofibrosis was a rare event in this cohort (2.5%). These results highlight the biological and prognostic relevance of molecular profile in TN-ET.